Preserving the Immune Reservoir: Why Excessive Lymph Node Dissection Hinders Immunotherapy in Recurrent Biliary Tract Cancer

MedXY Editorial Team•Jan 11, 2026•Gastroenterology

Extensive dissection of non-metastatic tumor-draining lymph nodes (TDLNs-) significantly reduces progression-free survival (PFS) in patients with recurrent biliary tract cancer (BTC) receiving immunotherapy.
Non-metastatic lymph nodes serve as a critical reservoir for TCF-1+PD-1-CD8+ tumor-specific memory T cells and CD11c+ conventional dendritic cells.
Multiplex immunofluorescence (mIF) analysis indicates that TDLNs- possess a more favorable immune microenvironment compared to metastatic lymph nodes (TDLNs+), which are characterized by terminally exhausted T cells and regulatory T cells.
A selective lymphadenectomy approach that preserves TDLNs- while clearing TDLNs+ may optimize outcomes for patients undergoing postoperative immunotherapy.

MedXY registered readers

Sign in free to continue reading

Create or use your MedXY account to unlock the complete article.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Extensive dissection of non-metastatic tumor-draining lymph nodes (TDLNs-) significantly reduces progression-free survival (PFS) in patients with recurrent biliary tract cancer (BTC) receiving immunotherapy.
Non-metastatic lymph nodes serve as a critical reservoir for TCF-1+PD-1-CD8+ tumor-specific memory T cells and CD11c+ conventional dendritic cells.
Multiplex immunofluorescence (mIF) analysis indicates that TDLNs- possess a more favorable immune microenvironment compared to metastatic lymph nodes (TDLNs+), which are characterized by terminally exhausted T cells and regulatory T cells.
A selective lymphadenectomy approach that preserves TDLNs- while clearing TDLNs+ may optimize outcomes for patients undergoing postoperative immunotherapy.